Vault-13

Stonepine Capital Management, LLC

Bend, OR · CIK 1440771 · 13F filing filed 2023-08-11

SEC-registered investment adviser since 2026 · limited liability company

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
Bend, OR (main office)United States United Statesabout 1
Sausalito, CA2 officesUnited States United States2

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$277.2m reported value -7.0% vs Q1 2023
21positions
84.2%in top 10
6 new 8 added 7 reduced 7 sold out vs Q1 2023

Holdings, Q2 2023

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 QUIDELORTHO CORP COM QDEL QDEL 619,426 $51.3m18.51% 18.51% AddedShares held: Q3 2022 501.6k, Q4 2022 300.0k, Q1 2023 279.1k, Q2 2023 619.4k +340.3k +340,345 122.0%
2 EVOLUS INC COM EOLS EOLS 4,506,197 $32.8m11.82% 11.82% AddedShares held: Q3 2022 200.0k, Q4 2022 834.4k, Q1 2023 578.8k, Q2 2023 4.5m +3.9m +3,927,402 678.5%
3 ADMA BIOLOGICS INC COM ADMA ADMA 8,793,321 $32.4m11.70% 11.70% AddedShares held: Q3 2022 5.0m, Q4 2022 6.9m, Q1 2023 7.7m, Q2 2023 8.8m +1.1m +1,131,631 14.8%
4 GALAPAGOS NV SPON ADR LKFT LKFT 682,664 $27.8m10.01% 10.01% ReducedShares held: Q3 2022 0, Q4 2022 194.8k, Q1 2023 782.3k, Q2 2023 682.7k -99.6k -99,625 -12.7%
5 AMYLYX PHARMACEUTICALS INC COM AMLX AMLX 1,121,028 $24.2m8.72% 8.72% NewShares held: Q3 2022 0, Q4 2022 0, Q1 2023 0, Q2 2023 1.1m
6 MAXCYTE INC COM MXCT MXCT 3,966,916 $18.2m6.57% 6.57% AddedShares held: Q3 2022 0, Q4 2022 273.3k, Q1 2023 2.7m, Q2 2023 4.0m +1.3m +1,259,826 46.5%
7 XERIS BIOPHARMA HOLDINGS INC COM XERS XERS 5,500,228 $14.4m5.20% 5.20% ReducedShares held: Q3 2022 12.9m, Q4 2022 11.2m, Q1 2023 8.6m, Q2 2023 5.5m -3.1m -3,139,977 -36.3%
8 THIRD HARMONIC BIO INC COM COM 2,793,149 $13.4m4.85% 4.85% ReducedShares held: Q3 2022 0, Q4 2022 2.0m, Q1 2023 3.1m, Q2 2023 2.8m -338.8k -338,846 -10.8%
9 ATYR PHARMA INC COM NEW ATYR ATYR 4,627,224 $10.0m3.61% 3.61% ReducedShares held: Q3 2022 601.0k, Q4 2022 0, Q1 2023 4.8m, Q2 2023 4.6m -198.5k -198,498 -4.1%
10 X4 PHARMACEUTICALS INC COM COM 4,605,263 $8.9m3.22% 3.22% NewShares held: Q3 2022 0, Q4 2022 0, Q1 2023 0, Q2 2023 4.6m
11 SCYNEXIS INC COM NEW COM NEW 2,946,346 $8.7m3.14% 3.14% AddedShares held: Q3 2022 0, Q4 2022 0, Q1 2023 450.0k, Q2 2023 2.9m +2.5m +2,496,346 554.7%
12 XOMA ROYALTY CORPORATION COM NEW XOMA XOMA 349,399 $6.6m2.38% 2.38% AddedShares held: Q3 2022 64.5k, Q4 2022 64.5k, Q1 2023 318.1k, Q2 2023 349.4k +31.3k +31,303 9.8%
13 REZOLUTE INC COM NEW RZLT RZLT 3,072,476 $6.1m2.19% 2.19% ReducedShares held: Q3 2022 3.0m, Q4 2022 3.0m, Q1 2023 3.1m, Q2 2023 3.1m -15.2k -15,173 -0.5%
14 TELA BIO INC COM TELA TELA 482,619 $4.9m1.76% 1.76% NewShares held: Q3 2022 0, Q4 2022 0, Q1 2023 0, Q2 2023 482.6k
15 UROGEN PHARMA LTD COM URGN URGN 448,508 $4.6m1.67% 1.67% ReducedShares held: Q3 2022 1.1m, Q4 2022 1.3m, Q1 2023 701.5k, Q2 2023 448.5k -253.0k -253,027 -36.1%
16 EXAGEN INC COM XGN XGN 1,049,352 $3.0m1.10% 1.10% AddedShares held: Q3 2022 1.3m, Q4 2022 854.0k, Q1 2023 1.0m, Q2 2023 1.0m +12.3k +12,278 1.2%
17 GAMIDA CELL LTD SHS SHS 1,500,000 $2.9m1.04% 1.04% NewShares held: Q3 2022 0, Q4 2022 0, Q1 2023 0, Q2 2023 1.5m
18 ATEA PHARMACEUTICALS INC COM AVIR AVIR 752,088 $2.8m1.01% 1.01% AddedShares held: Q3 2022 0, Q4 2022 0, Q1 2023 684.5k, Q2 2023 752.1k +67.6k +67,580 9.9%
19 DELCATH SYS INC COM NEW DCTH DCTH 378,787 $2.1m0.76% 0.76% NewShares held: Q3 2022 0, Q4 2022 0, Q1 2023 0, Q2 2023 378.8k
20 CASTLE BIOSCIENCES INC COM CSTL CSTL 91,978 $1.3m0.46% 0.46% ReducedShares held: Q3 2022 0, Q4 2022 178.2k, Q1 2023 292.9k, Q2 2023 92.0k -200.9k -200,888 -68.6%
21 AYTU BIOPHARMA INC COM AYTU AYTU 472,369 $755.8k0.27% 0.27% NewShares held: Q3 2022 0, Q4 2022 0, Q1 2023 0, Q2 2023 472.4k

Sold out since Q1 2023

SecurityTickerShares held beforeValue then
AMRYT PHARMA PLC 6,278,085 $91.5m6.3m shares
CTI BIOPHARMA CORP 6,535,674 $27.4m6.5m shares
DYNAVAX TECHNOLOGIES CORP DVAX DVAX 416,519 $4.1m416.5k shares
APOLLO ENDOSURGERY INC 370,000 $3.7m370.0k shares
TRAVERE THERAPEUTICS INC TVTX TVTX 132,005 $3.0m132.0k shares
CONFORMIS INC CFMS CFMS 402,651 $648.3k402.7k shares
CIDARA THERAPEUTICS INC 1,000 $1.3k1.0k shares

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
QUOIN PHARMACEUTICALS LTD QNRX · 13G · filed 2026-05-15 QNRX 10.0% -0.6 pts 13G 2026-05-15
AEON BIOPHARMA INC AEON · 13G · filed 2026-07-21 AEON 9.9%≈ $3.9m new 13G 2026-07-21
AZITRA INC 13G · filed 2026-06-22 9.9% new 13G 2026-06-22
ELOXX PHARMACEUTICALS INC ELOX · 13G · filed 2026-06-16 ELOX 9.9%≈ $5.6m new 13G 2026-06-16
SINTX TECHNOLOGIES INC SINT · 13G · filed 2026-06-09 SINT 9.9%≈ $1.2m new 13G 2026-06-09
CNS PHARMACEUTICALS INC CNSP · 13G · filed 2026-05-15 CNSP 9.9%≈ $760.7k +2.0 pts 13G 2026-05-15
CELLECTAR BIOSCIENCES INC CLRB · 13G · filed 2026-05-11 CLRB 9.9%≈ $2.4m new 13G 2026-05-11
CURIS INC 13G · filed 2026-03-27 9.9%≈ $2.1m new 13G 2026-03-27
IN8BIO INC INAB · 13G · filed 2025-12-22 INAB 9.9%≈ $1.4m new 13G 2025-12-22
AYTU BIOPHARMA INC AYTU · 13G · filed 2025-08-13 AYTU 9.9%≈ $1.9m 13G 2025-08-13
OPTINOSE INC OPTN · 13G · filed 2025-05-14 OPTN 7.8% +1.9 pts 13G 2025-05-14
FEMASYS INC FEMY · 13G · filed 2026-08-31 FEMY 7.2%≈ $2.6m new 13G 2026-08-31
EDESA BIOTECH INC EDSA · 13G · filed 2026-08-26 EDSA 6.9%≈ $5.9m +6.6 pts 13G 2026-08-26
CALCIMEDICA INC 13G · filed 2026-08-25 6.0%≈ $2.2m +1.4 pts 13G 2026-08-25
TELA BIO INC TELA · 13G · filed 2025-02-13 TELA 6.0%≈ $1.8m 13G 2025-02-13
PASITHEA THERAPEUTICS CORP KTTA · 13G · filed 2026-06-23 KTTA 5.8%≈ $1.0m new 13G 2026-06-23